ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 327 filers reported holding ROYALTY PHARMA PLC in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,989,195 | +31.7% | 2,026,131 | +49.2% | 0.05% | +30.6% |
| Q2 2023 | $41,754,265 | -10.4% | 1,358,304 | +5.0% | 0.04% | -12.2% |
| Q1 2023 | $46,587,727 | -14.7% | 1,293,026 | -6.4% | 0.04% | -12.8% |
| Q4 2022 | $54,617,351 | +62.5% | 1,382,018 | +65.2% | 0.05% | +51.6% |
| Q3 2022 | $33,617,000 | +29.0% | 836,659 | +35.0% | 0.03% | +29.2% |
| Q2 2022 | $26,056,000 | +4.6% | 619,798 | -3.1% | 0.02% | +26.3% |
| Q1 2022 | $24,909,000 | -9.7% | 639,350 | -7.7% | 0.02% | +5.6% |
| Q4 2021 | $27,595,000 | +6.3% | 692,474 | -3.6% | 0.02% | -5.3% |
| Q3 2021 | $25,964,000 | -11.4% | 718,425 | +0.5% | 0.02% | -13.6% |
| Q2 2021 | $29,315,000 | -11.0% | 715,172 | -5.2% | 0.02% | -12.0% |
| Q1 2021 | $32,922,000 | +146.1% | 754,737 | +182.3% | 0.02% | +150.0% |
| Q4 2020 | $13,379,000 | +70.1% | 267,320 | +43.0% | 0.01% | +42.9% |
| Q3 2020 | $7,866,000 | – | 186,976 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |